These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27814987)

  • 1. NICE approves osimertinib for advanced lung cancer.
    Burki TK
    Lancet Respir Med; 2016 Dec; 4(12):954. PubMed ID: 27814987
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC.
    Chen K; Zhou F; Shen W; Jiang T; Wu X; Tong X; Shao YW; Qin S; Zhou C
    J Thorac Oncol; 2017 Jun; 12(6):e65-e68. PubMed ID: 28093244
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of a NSCLC patient with osimertinib based on the detection of the EGFR T790M resistance mutation in cerebrospinal fluid.
    Théoleyre S; Masson I; Herbreteau G; Vallée A; Sénellart H; Denis MG
    Lung Cancer; 2017 Dec; 114():111-112. PubMed ID: 29096978
    [No Abstract]   [Full Text] [Related]  

  • 4. Osimertinib effective in EGFR T790M-positive lung cancer.
    Mayor S
    Lancet Oncol; 2017 Jan; 18(1):e9. PubMed ID: 27989430
    [No Abstract]   [Full Text] [Related]  

  • 5. Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung Cancer.
    York ER; Varella-Garcia M; Bang TJ; Aisner DL; Camidge DR
    J Thorac Oncol; 2017 Jul; 12(7):e85-e88. PubMed ID: 28274743
    [No Abstract]   [Full Text] [Related]  

  • 6. [Non-Small Cell Lung Cancer - Development of Parallel Mechanisms of Resistance].
    Moeller M; Siebolts U; Wickenhauser C; Schuette W
    Pneumologie; 2018 Jul; 72(7):503-506. PubMed ID: 29466812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Okuno T; Arakawa S; Yoshida T; Ohe Y
    Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
    [No Abstract]   [Full Text] [Related]  

  • 8. First-Line Osimertinib in Patients with Treatment-Naive Somatic or Germline EGFR T790M-Mutant Metastatic NSCLC.
    Ancevski Hunter K; Friedland DM; Villaruz LC; Burns TF
    J Thorac Oncol; 2018 Jan; 13(1):e3-e5. PubMed ID: 28989039
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
    Stratmann JA; Michels S; Hornetz S; Christoph DC; Sackmann S; Spengler W; Bischoff H; Schäfer M; Alt J; Müller A; Laack E; Kimmich M; Griesinger F; Sebastian M
    J Cancer Res Clin Oncol; 2018 Dec; 144(12):2457-2463. PubMed ID: 30244389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
    Chic N; Mayo-de-Las-Casas C; Reguart N
    J Thorac Oncol; 2017 Jun; 12(6):e78-e80. PubMed ID: 28532569
    [No Abstract]   [Full Text] [Related]  

  • 11. Osimertinib improves progression-free survival in NSCLC.
    Stirrups R
    Lancet Oncol; 2018 Jan; 19(1):e10. PubMed ID: 29175151
    [No Abstract]   [Full Text] [Related]  

  • 12. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
    Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
    Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
    Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
    J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.
    Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G
    Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
    Sullivan I; Planchard D
    Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Osimertinib (Tagrisso
    Giroux Leprieur E; Cortot AB; Cadranel J; Wislez M
    Bull Cancer; 2016 Oct; 103(10):815-821. PubMed ID: 27641462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib.
    Jenkins S; Yang JC; Jänne PA; Thress KS; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd FA
    J Thorac Oncol; 2017 Aug; 12(8):1247-1256. PubMed ID: 28527899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
    Minari R; Bordi P; La Monica S; Squadrilli A; Leonetti A; Bottarelli L; Azzoni C; Lagrasta CAM; Gnetti L; Campanini N; Petronini PG; Alfieri R; Tiseo M
    J Thorac Oncol; 2018 Jun; 13(6):e89-e91. PubMed ID: 29596911
    [No Abstract]   [Full Text] [Related]  

  • 20. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
    Yan Y; Jiang G; Ma W; Li T; Wang L
    Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.